← FDA DRUG APPROVALS

FDA ANDA · ANDA209634

DOCETAXEL ANHYDROUS

Sponsor: MEITHEAL

APPLICATION
ANDA209634
TYPE
ANDA
ORIGINAL APPROVAL
2018-08-24
LATEST ACTION
2023-09-15
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOCETAXELPrescription
DOCETAXEL 160MG/16ML (10MG/ML) · INJECTABLE · INJECTION
DOCETAXELPrescription
DOCETAXEL 20MG/2ML (10MG/ML) · INJECTABLE · INJECTION
DOCETAXELPrescription
DOCETAXEL 80MG/8ML (10MG/ML) · INJECTABLE · INJECTION

Approval history

2023-09-15Labeling · Supplement 6 · standardAP
2019-12-13Labeling · Supplement 3 · standardAP
2019-03-13Labeling · Supplement 2 · standardAP
2018-08-24UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →